Montelukast for the treatment of asthma in the adult population

Bibliography

• Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med 1990;323:645-55
   PubMed Web of Science ®Google Scholar
• Holgate ST, Frew AJ. Choosing therapy for childhood asthma. N Engl J Med 1997;337:1690-2
   PubMed Web of Science ®Google Scholar
• Lougheed DM, Lemiere C, Dell SD, Canadian Thoracic Society Asthma Continuum – 2010 consensus summary for children six years of age and over, and adults. Can Respir J 2010;17:15-24
   PubMed Web of Science ®Google Scholar
• Masoli M, Fabian D, Holt S, The global burden of asthma: executive summary of the GINA dissemination committee report. Allergy 2004;59:469-78
   PubMed Web of Science ®Google Scholar
• Benninger MS, Waters H. Montelukast: pharmacology, safety, tolerability and efficacy. Clin Med Ther 2009;1:1253-61
   Google Scholar
• Pawankar R. Allergic rhinitis and asthma: the link, the new ARIA classification and global approaches to treatment. Curr Opin All Clin Immunol 2004;4(1):1-4
   PubMed Web of Science ®Google Scholar
• Guerra S, Sherrill DL, Martinez FD, Rhinitis as an independent risk factor for adult-onset asthma. J Allergy Clin Immunol 2002;109(3):419-25
   PubMed Web of Science ®Google Scholar
• British Thoracic Society. British guideline on the management of asthma. Thorax 2008;63(4):1-121
   PubMedGoogle Scholar
• Bateman ED, Hurd SS, Barnes PJ, Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008;31(1):143-78
   PubMed Web of Science ®Google Scholar
• Peters SP, Kunselman SJ, Icitovic N, Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 2010;363:1715-26
   PubMed Web of Science ®Google Scholar
• Cox G, Thomson NC, Rubin AS, Asthma control during the year after bronchial thermoplasty. N Engl J Med 2007;356:1327-37
   PubMed Web of Science ®Google Scholar
• Merck Frosst Canada. (2011). Research & Development: Major Accomplishments: Singulair. Available from: http://www.merckfrosst.ca/mfcl/en/corporate/research/accomplishments/singulair. html
   Google Scholar
• Walia M, Lodha R, Kabra SK. Montelukast in pediatric asthma management. Indian J Pediatr 2006;73(4):276-82
   Google Scholar
• Cheng H, Leff JA, Amin R, Pharmacokinetics, bioavailability and safety of montelukast sodium (MK-0476) in healthy males and females. Pharm Res 1996;13:445-8
   PubMed Web of Science ®Google Scholar
• Bjermer L, Bisgaard H, Bousquet J, Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. BMJ 2003;327:891-7
   PubMed Web of Science ®Google Scholar
• Braccioni F, Dorman SC, O'Byrne PM, The effect of cysteinyl leukotrienes on growth of eosinophil progenitors from peripheral blood and bone marrow of atopic subjects. J Allergy Clin Immunol 2002;110(1):96-101
   PubMed Web of Science ®Google Scholar
• Laviolette M, Malmstrom K, Lu S, Montelukast added to inhaled beclomethasone in treatment of asthma. Am J Respir Crit Care Med 1999;160(6):1862-8
   PubMed Web of Science ®Google Scholar
• Vaquerizo MJ, Casan P, Castillo J, Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax 2003;58(3):204-10
   PubMed Web of Science ®Google Scholar
• Price DB, Hernandez D, Magyar P, Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003;8(3):211-16
   Google Scholar
• Lofdahl CG, Reiss TF, Leff JA, Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ 1999;319(7202):87-90
   PubMed Web of Science ®Google Scholar
• Tohda Y, Fujimura M, Taniguchi H, Leukotriene receptor antagonist, montelukast, can reduce the need for inhaled steroid while maintaining the clinical stability of asthmatic patients. Clin Exp Allergy 2002;32(8):1180-6
   PubMed Web of Science ®Google Scholar
• Ducharme FM, Hicks GC. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev 2002;(3):CD002314
   Google Scholar
• Nelson HS, Busse WW, Kerwin E, Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 2000;106(6):1088-95
   PubMed Web of Science ®Google Scholar
• Fish JE, Israel E, Murray JJ, Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest 2001;120(2):423-30
   PubMed Web of Science ®Google Scholar
• Ringdal N, Eliraz A, Pruzinec R, The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. Respir Med 2003;97(3):234-41
   PubMed Web of Science ®Google Scholar
• Ilowite J, Webb R, Friedman B, Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study. Ann Allergy Asthma Immunol 2004;92(6):641-8
   PubMed Web of Science ®Google Scholar
• Bjermer L, Bisgaard H, Bousquet J, Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. BMJ 2003;327(7420):891
   PubMed Web of Science ®Google Scholar
• Joos S, Miksch A, Szecsenyi J, Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review. Thorax 2008;63(5):453-62
   PubMed Web of Science ®Google Scholar
• McIvor RA, Pizzichini E, Turner MO, Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998;158(3):924-30
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Buckley NS, Ormiston TM, Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006;144(12):904-12
   PubMed Web of Science ®Google Scholar
• Ducharme FM, Ni Chroinin M, Greenstone I, Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev 2010;(5):CD005535
   PubMed Web of Science ®Google Scholar
• Ducharme FM, Ni Chroinin M, Greenstone I, Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Syst Rev 2010;(4):CD005533
   PubMed Web of Science ®Google Scholar
• Ernst P, McIvor A, Ducharme FM, Safety and effectiveness of long-acting inhaled beta-agonist bronchodilators when taken with inhaled corticosteroids. Ann Intern Med 2006;145(9):692-4
   PubMed Web of Science ®Google Scholar
• Philip G, Nayak AS, Berger WE, The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr Med Res Opin 2004;20(10):1549-58
   PubMed Web of Science ®Google Scholar
• Vignola AM, Chanez P, Bousquet J. The relationship between asthma and allergic rhinitis: exploring the basis for a common pathophysiology. Clin Exp Allergy Rev 2003;3:63-8
   Google Scholar
• Bourdin A, Gras D, Vachier I, Chanez P. Upper airway x 1: allergic rhinitis and asthma: united disease through epithelial cells. Thorax 2009;64(11):999-1004
   PubMed Web of Science ®Google Scholar
• Braunstahl GJ, Overbeek SE, Fokkens WJ, Segmental bronchoprovocation in allergic rhinitis patients affects mast cell and basophil numbers in nasal and bronchial mucosa. Am J Respir Crit Care Med 2001;164:858-65
   PubMed Web of Science ®Google Scholar
• Passalacqua G, Ciprandi G, Canonica GW. United airways disease: therapeutic aspects. Thorax 2000;55:S26-7
   PubMed Web of Science ®Google Scholar
• Greisner WA, Settipane RJ, Settipane GA. Co-existence of asthma and allergic rhnitis: a 23-year follow-up study of college students. Allergy Asthma Proc 1998;19(4):185-8
   PubMed Web of Science ®Google Scholar
• Moller C, Dreborg S, Ferdousi HA, Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002;109:251-6
   PubMed Web of Science ®Google Scholar
• Price D, Zhang Q, Kocevar VS, Effect of a concomitant diagnosis of allergic rhinitis on asthma-related health care use by adults. Clin Exp Allergy 2005;35:282-7
   PubMed Web of Science ®Google Scholar
• Busse WW, Casale TB, Dykewicz MS, Efficacy of montelukast during the allergy season in patients with chronic asthma and seasonal aeroallergen sensitivity. Ann Allergy Asthma Immunol 2006;96:60-8
   PubMed Web of Science ®Google Scholar
• Price DB, Swern A, Tozzi CA, Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT trial. Allergy 2006;61(6):737-42
   PubMed Web of Science ®Google Scholar
• Virchow JC, Bachert C. Efficacy and safety of montelukast in adults with asthma and allergic rhinitis. Respir Med 2006;100(11):1952-9
   PubMed Web of Science ®Google Scholar
• Keith PK, Koch C, Djandji M, Montelukast as add-on therapy with inhaled corticosteroids or inhaled corticosteroids and long acting beta-2-agonist in the management of patients diagnosed with asthma and concurrent allergic rhinitis (the RADAR trial). Can Respir J 2009;16(Suppl A):17A-31A
   PubMedGoogle Scholar
• McIvor RA, Sampalis J. Real-life asthma care in Canada. Can Respir J 2009;16(Suppl A):3A-6A
   Google Scholar
• Herland K, Akselsen JP, Skjonsberg OH, How representative are clinical study patients with asthma or COPD for a larger ‘real life’ population of patients with obstructive lung disease? Respir Med 2005;99:11-19
   PubMed Web of Science ®Google Scholar
• Dupont L, Potvin E, Korn D. Improving asthma control in patients suboptimally controlled on inhaled steroids and long acting beta agonists: the addition of montelukast in an open-label pilot study. Curr Med Res Opin 2005;21(6):863-942
   PubMed Web of Science ®Google Scholar
• Korn D, Van den Brande D, Potvin E, Efficacy of add-on montelukast in patients with non-controlled asthma: a Belgian open label study. Curr Med Res Opin 2009;25(2):489-97
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Foucart S, Coyle S, Montelukast as add-on therapy to inhaled corticosteroids in the management of asthma (SAS trial). Can Respir J 2009;16(Suppl A):5A-14A
   Google Scholar
• Virchow JC, Mehta A, Ljungblad L, Mitfessel H. Add-on montelukast in inadequately controlled asthma patients in a 6 month open label study: The montelukast in chronic asthma (MONICA) study. Respir Med 2010;104(5):644-51
   PubMed Web of Science ®Google Scholar
• Schlick W, Pohl W, Pfeiffer KP, Evaluation of 3-5 months' add-on therapy with montelukast in patients with non-controlled asthma in Austria: the STAR open-label, real world, observational study. Curr Med Res Opin 2010;26(3):561-70
   PubMed Web of Science ®Google Scholar
• McIvor RA, Kaplan A, Koch C, Montelukast as an alternative to low-dose inhaled corticosteroids in the management of asthma (SIMPLE trial). Can Respir J 2009;16(Suppl A):5A-14A
   Google Scholar
• Riccioni G, Bucciarelli T, Mancini B, Antileukotriene drugs: clinical application, effectiveness and safety. Curr Med Chem 2007;14:1966-77
   PubMed Web of Science ®Google Scholar
• Echsler ME, Finn D, Gunawardena D, Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest 2000;117:708-13
   PubMed Web of Science ®Google Scholar
• S Bibby S, Healy B, Steele R, Association between leukotriene receptor antagonist therapy and Churg-Strauss syndrome: an analysis of the FDA AERS database. Thorax 2010;65:132-8
   PubMed Web of Science ®Google Scholar
• Diamant Z, Mantzouranis E, Bjermer L. Montelukast in the treatment of asthma and beyond. Expert Rev Clin Immunol 2009;5(6):639-58
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. (2010). Updated information on leukotriene inhibitors. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm165489.htm
   Google Scholar
• Manalai P, Woo JM, Postolache TT. Suicidality and montelukast. Expert Opin Drug Saf 2009;8:273-82
   PubMed Web of Science ®Google Scholar
• Majid H, Kao C. Utility of exhaled nitric oxide in the diagnosis and management of asthma. Curr Opin Pulm Med 2010;16(1):42-7
   PubMed Web of Science ®Google Scholar
• Van Adelsberg J, Moy J, Wei LX, Safety, tolerability, and exploratory efficacy of montelukast in 6- to 24-month-old patients with asthma. Curr Med Res Opin 2005;21(6):971-9
   PubMed Web of Science ®Google Scholar
• Philip G, Pedinoff A, Vandormael K, A phase I randomized, placebo-controlled, dose-exploration study of single-dose inhaled montelukast in patients with chronic asthma. J Asthma 2010;47(10):1078-84
   PubMed Web of Science ®Google Scholar
• Morris CR, Becker AB, Pinieiro A, A randomized, placebo-controlled study of intravenous montelukast in children with acute asthma. Ann Allergy Asthma Immunol 2010;104(2):161-71
   PubMed Web of Science ®Google Scholar
• Camargo CA Jr, Gurner DM, Smithline HA, A randomized placebo-controlled study of intravenous montelukast for the treatment of acute asthma. J Allergy Clin Immunol 2010;125(2):374-80
   PubMed Web of Science ®Google Scholar
• DuBuske LM, Grossman J, Dube LM, Randomized trial of zileuton in patients with moderate asthma: effect of reduced dosing frequency and amounts on pulmonary function and asthma symptoms. Am J Manag Care 1997;3(4):633-40
   PubMed Web of Science ®Google Scholar